CAJ | 학술논문

目的观察培美曲塞联合顺铂同步放化疗治疗局部晚期肺腺癌的近期疗效和急性毒副反应.方法 18例经病理确诊的局部晚期肺腺癌患者(ⅢA或ⅢB)接受同步放化疗,放疗均采用IMRT计划,照射剂量60～70 y,1.8～2 Gy/次,5次/周.同步化疗方案为培美曲塞(500 mg/m2 d1),顺铂(75 mg/m2d1).3周重复,共2个周期,与放疗同期进行.部分患者接受1～2周期的新辅助化疗,化疗方案同同步化疗方案.结果完全缓解(CR)3例,部分缓解(PR) 12例,稳定(SD)2例,进展(PD)1例,客观有效率(CR+PR)为83.4％,疾病控制率(CR+PR+SD)为94.5％.主要毒副反应是放射性食管炎、骨髓抑制和轻度胃肠道反应,经对症支持治疗患者均能耐受.结论培美曲塞联合顺铂同步放化疗治疗局部晚期肺腺癌,近期疗效肯定,耐受性良好,远期疗效和晚期并发症有待进一步观察.
목적 관찰배미곡새연합순박동보방화료치료국부만기폐선암적근기료효화급성독부반응.방법 18례경병리학진적국부만기폐선암환자(ⅢA혹ⅢB)접수동보방화료,방료균채용IMRT계화,조사제량60～70 y,1.8～2 Gy/차,5차/주.동보화료방안위배미곡새(500 mg/m2 d1),순박(75 mg/m2d1).3주중복,공2개주기,여방료동기진행.부분환자접수1～2주기적신보조화료,화료방안동동보화료방안.결과 완전완해(CR)3례,부분완해(PR) 12례,은정(SD)2례,진전(PD)1례,객관유효솔(CR+PR)위83.4％,질병공제솔(CR+PR+SD)위94.5％.주요독부반응시방사성식관염、골수억제화경도위장도반응,경대증지지치료환자균능내수.결론 배미곡새연합순박동보방화료치료국부만기폐선암,근기료효긍정,내수성량호,원기료효화만기병발증유대진일보관찰.
Objective To evaluate short-term effect and acute adverse reactions of pemetrexed combined with cisplatin concurrent chemoradiotherapy in locally advanced adenocarcinoma of lung.Methods 18 patients with locally advanced adenocarcinoma of lung received concurrent chemoradiotherapy(pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 were administrated to patients on the first day of every 3 weeks for 2 cycles),part of the patients were administrated neoadjuvant chemotherapy for 1-2 cycles.Radiotherapy adopted IMRT with a total of 60-70 Gy,1.8-2 Gy/f,5 times per week.Results There were 3 cases of CR,12 cases of PR,2 cases of SD,1 case of PD.The overall response rate (CR + PR) was 83.4％ and the clinical benefiting rate (CR + PR + SD) was 94.5％.The main adverse effects were radioactive esophagitis,bonemarrow suppression and mild gastrointestinal toxicit,tolerated by patients with support treatment.Conclusions Pemetrexed combined with cisplatin concurrent chemoradiotherapy in locally advanced adenocarcinoma of lung has good short-term effect,safety and tolerability.Long-term survival and late complications need further observation.